Year: 2025

  • Proposed Accelerated Bookbuild for Vendor Placing and Issue of Equity

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce a proposed placing of 7,100,000 existing ordinary shares of 10p each (“Ordinary Shares”) held by Lanstead Capital L.P. (“Lanstead”) to new institutional investors (the “Vendor Placing”). The Company also announces a proposed placing of up to approximately £0.8 million (before expenses)…

  • Close of Accelerated Bookbuild

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that further to the announcement made earlier today entitled “Proposed Accelerated Bookbuild for Vendor Placing and Issue of Equity”, the accelerated bookbuild (the “Bookbuild”) process has now successfully closed. The Company has placed 7,100,000 existing ordinary shares of 10p each (“Ordinary…

  • INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2016

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2016 (the “Period”). Key Highlights (including post Period review) Lupuzor™: is the Company’s lead programme for the potential breakthrough compound for Lupus a potential life threatening auto-immune…

  • Update on Lupuzor’s Pivotal Phase III Study – 11 US Sites Now Open, 5 European Countries Now Recruiting

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. Key Trial Highlights Total 11 sites now active in US 5 European…

  • ImmuPharma Invited to Open an Additional Site in Mauritius

    Up to 30 Lupus patients ready for enrolment ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. ImmuPharma has been requested…

  • ImmuPharma Invited to Open an Additional Site in Mauritius

    Up to 30 Lupus patients ready for enrolment ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. ImmuPharma has been requested…

  • Northland Capital Appointed as Joint Broker

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces the appointment of Northland Capital Partners as joint broker to the Company, alongside Panmure Gordon with immediate effect.

  • Immupharma Hosts Lupuzor ™ Symposium with Lupuzor’s™ Inventor, Prof. Sylviane Muller

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to confirm that today and tomorrow, 8 & 9 June, it is hosting a number of presentations on Lupuzor™, the Company’s lead compound for the potential treatment of Lupus, a chronic auto-immune disease, currently in a pivotal Phase III trial. This event, to…

  • First European Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. ImmuPharma is pleased to confirm that the first European sites opened…

  • Notification of Major Interest by Alto Invest to 4.15%

    ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that on 30 May 2016 it received notification by Alto Invest and its subsidiaries (“Alto”) confirming that it has increased its holding to 5,053,548 million Ordinary Shares in the capital of the Company. This represents 4.15% of ImmuPharma’s total voting…